CYP2D6 polymorphism in a Mexican American population

R. Mendoza, Yu-Jui Yvonne Wan, R. E. Poland, M. Smith, K. M. Lin

Research output: Contribution to journalArticle

Abstract

Despite being one of the fastest growing populations in America, pharmacogenetic data is largely unavailable for Mexican Americans. The CYP2D6 genotype and dextromethorphan hydroxylation phenotype was studied in 248 Mexican American subjects from Los Angeles County. The incidence of poor metabolizer phenotype was 3.0%, and the mean Log10 dextromethorphan/dextrorphan ratio was -2.47 indicating Mexican Americans have an increased metabolic rate when compared to published data on Caucasian and African American populations. The CYP2D6 genotype was analyzed by allele-specific PCR analysis for the presence of mutant or null alleles at the CYP2D6 locus. The CYP2D6*4 mutation allele gene frequency was 10.1% and the allelic frequency for the CYP2D6 duplication mutation was 1%. Four subjects were homozygous for the CYP2D6*4 mutation. The allelic frequency for the CYP2D6*10 mutation was 17.1%. Very few subjects were shown to possess the CYP2D6*3, CYP2D6*5, and CYP2D6*17 mutant alleles. A strong correlation between genotype and phenotype was present. The racial admixture in present day Mexican Americans, largely a blend of indigenous Indian groups of Mexico and Spanish genetic influences, is reflected in the results from our genotypic analysis.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - 2001

Fingerprint

Cytochrome P-450 CYP2D6
Population
Dextromethorphan
Mutation
Alleles
Gene Frequency
Dextrorphan
Genotype
Phenotype
Los Angeles
Pharmacogenetics
Genetic Association Studies
Hydroxylation
Mexico
African Americans
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mendoza, R., Wan, Y-J. Y., Poland, R. E., Smith, M., & Lin, K. M. (2001). CYP2D6 polymorphism in a Mexican American population. Clinical Pharmacology and Therapeutics, 69(2).

CYP2D6 polymorphism in a Mexican American population. / Mendoza, R.; Wan, Yu-Jui Yvonne; Poland, R. E.; Smith, M.; Lin, K. M.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 2001.

Research output: Contribution to journalArticle

Mendoza, R, Wan, Y-JY, Poland, RE, Smith, M & Lin, KM 2001, 'CYP2D6 polymorphism in a Mexican American population', Clinical Pharmacology and Therapeutics, vol. 69, no. 2.
Mendoza, R. ; Wan, Yu-Jui Yvonne ; Poland, R. E. ; Smith, M. ; Lin, K. M. / CYP2D6 polymorphism in a Mexican American population. In: Clinical Pharmacology and Therapeutics. 2001 ; Vol. 69, No. 2.
@article{fd708d20b05f416e919270c85c2b34ff,
title = "CYP2D6 polymorphism in a Mexican American population",
abstract = "Despite being one of the fastest growing populations in America, pharmacogenetic data is largely unavailable for Mexican Americans. The CYP2D6 genotype and dextromethorphan hydroxylation phenotype was studied in 248 Mexican American subjects from Los Angeles County. The incidence of poor metabolizer phenotype was 3.0{\%}, and the mean Log10 dextromethorphan/dextrorphan ratio was -2.47 indicating Mexican Americans have an increased metabolic rate when compared to published data on Caucasian and African American populations. The CYP2D6 genotype was analyzed by allele-specific PCR analysis for the presence of mutant or null alleles at the CYP2D6 locus. The CYP2D6*4 mutation allele gene frequency was 10.1{\%} and the allelic frequency for the CYP2D6 duplication mutation was 1{\%}. Four subjects were homozygous for the CYP2D6*4 mutation. The allelic frequency for the CYP2D6*10 mutation was 17.1{\%}. Very few subjects were shown to possess the CYP2D6*3, CYP2D6*5, and CYP2D6*17 mutant alleles. A strong correlation between genotype and phenotype was present. The racial admixture in present day Mexican Americans, largely a blend of indigenous Indian groups of Mexico and Spanish genetic influences, is reflected in the results from our genotypic analysis.",
author = "R. Mendoza and Wan, {Yu-Jui Yvonne} and Poland, {R. E.} and M. Smith and Lin, {K. M.}",
year = "2001",
language = "English (US)",
volume = "69",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - CYP2D6 polymorphism in a Mexican American population

AU - Mendoza, R.

AU - Wan, Yu-Jui Yvonne

AU - Poland, R. E.

AU - Smith, M.

AU - Lin, K. M.

PY - 2001

Y1 - 2001

N2 - Despite being one of the fastest growing populations in America, pharmacogenetic data is largely unavailable for Mexican Americans. The CYP2D6 genotype and dextromethorphan hydroxylation phenotype was studied in 248 Mexican American subjects from Los Angeles County. The incidence of poor metabolizer phenotype was 3.0%, and the mean Log10 dextromethorphan/dextrorphan ratio was -2.47 indicating Mexican Americans have an increased metabolic rate when compared to published data on Caucasian and African American populations. The CYP2D6 genotype was analyzed by allele-specific PCR analysis for the presence of mutant or null alleles at the CYP2D6 locus. The CYP2D6*4 mutation allele gene frequency was 10.1% and the allelic frequency for the CYP2D6 duplication mutation was 1%. Four subjects were homozygous for the CYP2D6*4 mutation. The allelic frequency for the CYP2D6*10 mutation was 17.1%. Very few subjects were shown to possess the CYP2D6*3, CYP2D6*5, and CYP2D6*17 mutant alleles. A strong correlation between genotype and phenotype was present. The racial admixture in present day Mexican Americans, largely a blend of indigenous Indian groups of Mexico and Spanish genetic influences, is reflected in the results from our genotypic analysis.

AB - Despite being one of the fastest growing populations in America, pharmacogenetic data is largely unavailable for Mexican Americans. The CYP2D6 genotype and dextromethorphan hydroxylation phenotype was studied in 248 Mexican American subjects from Los Angeles County. The incidence of poor metabolizer phenotype was 3.0%, and the mean Log10 dextromethorphan/dextrorphan ratio was -2.47 indicating Mexican Americans have an increased metabolic rate when compared to published data on Caucasian and African American populations. The CYP2D6 genotype was analyzed by allele-specific PCR analysis for the presence of mutant or null alleles at the CYP2D6 locus. The CYP2D6*4 mutation allele gene frequency was 10.1% and the allelic frequency for the CYP2D6 duplication mutation was 1%. Four subjects were homozygous for the CYP2D6*4 mutation. The allelic frequency for the CYP2D6*10 mutation was 17.1%. Very few subjects were shown to possess the CYP2D6*3, CYP2D6*5, and CYP2D6*17 mutant alleles. A strong correlation between genotype and phenotype was present. The racial admixture in present day Mexican Americans, largely a blend of indigenous Indian groups of Mexico and Spanish genetic influences, is reflected in the results from our genotypic analysis.

UR - http://www.scopus.com/inward/record.url?scp=33748960962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748960962&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748960962

VL - 69

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -